Free Trial

STERIS (STE) Stock Forecast & Price Target

STERIS logo
$224.35 +1.29 (+0.58%)
Closing price 03/27/2025 03:59 PM Eastern
Extended Trading
$224.10 -0.24 (-0.11%)
As of 03/27/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STERIS - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
4

Based on 5 Wall Street analysts who have issued ratings for STERIS in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 5 analysts, 1 has given a hold rating, and 4 have given a buy rating for STE.

Consensus Price Target

$258.75
15.33% Upside
According to the 5 analysts' twelve-month price targets for STERIS, the average price target is $258.75. The highest price target for STE is $265.00, while the lowest price target for STE is $240.00. The average price target represents a forecasted upside of 15.33% from the current price of $224.35.
Get the Latest News and Ratings for STE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for STERIS and its competitors.

Sign Up

STE Analyst Ratings Over Time

TypeCurrent Forecast
3/28/24 to 3/28/25
1 Month Ago
2/27/24 to 2/26/25
3 Months Ago
12/29/23 to 12/28/24
1 Year Ago
3/29/23 to 3/28/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$258.75$258.75$262.50$239.60
Forecasted Upside15.33% Upside16.05% Upside26.21% Upside6.57% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Remove Ads

STE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

STE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

STERIS Stock vs. The Competition

TypeSTERISMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.82
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside15.33% Upside29,848.24% Upside17.91% Upside
News Sentiment Rating
Very Positive News

See Recent STE News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/6/2025JMP Securities
2 of 5 stars
Reni Benjamin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$265.00 ➝ $265.00+17.96%
2/6/2025Stephens
4 of 5 stars
Jacob Johnson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$240.00 ➝ $240.00+7.49%
2/3/2025Piper Sandler
2 of 5 stars
J. Bednar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$260.00 ➝ $265.00+21.26%
11/8/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
9/3/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$255.00 ➝ $265.00+9.11%
12/4/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$225.00 ➝ $215.00+5.65%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 06:46 AM ET.


Should I Buy STERIS Stock? STE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, March 22, 2025. Please send any questions or comments about these STERIS pros and cons to contact@marketbeat.com.

STERIS
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in STERIS plc:

  • STERIS plc has a strong net margin of 8.66%, indicating effective cost management and profitability, which can lead to higher returns for investors.
  • The company has a return on equity of 13.91%, suggesting that it is efficiently using shareholders' equity to generate profits, making it an attractive investment.
  • Recent analyst upgrades have set a target price of $265.00, indicating potential for stock appreciation from the current price of $220.34.
  • STERIS plc has a consistent dividend payout of $0.57 per share, translating to an annualized dividend of $2.28, providing a steady income stream for investors.
  • The company operates in the healthcare sector, which is generally resilient and can offer stability during economic downturns, making it a safer investment choice.

STERIS
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in STERIS plc for these reasons:

  • The stock has a high price-to-earnings ratio of 46.78, which may indicate that it is overvalued compared to its earnings, posing a risk for potential investors.
  • Despite a strong market capitalization of $21.65 billion, the stock has experienced volatility, with a one-year low of $197.82, suggesting potential instability.
  • With a payout ratio of 48.41%, there may be concerns about the sustainability of the dividend, especially if earnings do not grow as expected.
  • Recent trading activity shows a decline of $5.13 in stock price, which may indicate bearish sentiment among investors and could lead to further price drops.
  • While the company has received positive ratings, one analyst has issued a hold rating, suggesting that not all experts are confident in the stock's immediate prospects.

STE Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for STERIS is $258.75, with a high forecast of $265.00 and a low forecast of $240.00.

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last twelve months. There is currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STE shares.

According to analysts, STERIS's stock has a predicted upside of 15.33% based on their 12-month stock forecasts.

STERIS has been rated by research analysts at JMP Securities, Piper Sandler, and Stephens in the past 90 days.

Analysts like STERIS less than other "medical" companies. The consensus rating score for STERIS is 2.80 while the average consensus rating score for "medical" companies is 2.82. Learn more on how STE compares to other companies.


This page (NYSE:STE) was last updated on 3/28/2025 by MarketBeat.com Staff
From Our Partners